+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 1 Actively Recruiting clinical trials

F

Actively Recruiting

Researchers are evaluating CT-202, a new humanized T cell engaging bispecific antibody targeting nectin-4, in people with nectin-4 positive recurrent, unresectable, or metastatic triple negative breast cancer TNBC, colorectal cancer CRC, or urothelial cancer UC that are resistant to standard treatments. This Phase 1a1b trial aims to assess the safety, tolerability, and early signs of effectiveness of CT-202. Results from this study including pharmacokinetics, pharmacodynamics, efficacy, and safety will help determine the recommended dose for future studies. The study includes two parts Phase 1a dose escalation uses a Bayesian Optimal Interval design with step-up dosing every two weeks across approximately six dose levels. Participants will continue treatment until disease progression, unacceptable side effects, withdrawal, or investigator decision. Phase 1b dose expansion will test CT-202 at two or more doses and dosing schedules across 4 to 6 groups of up to 15 participants each, focusing on the same cancer types. Data from Phase 1b will guide the recommended Phase 2 dose. Participants will undergo regular evaluations including safety monitoring and tumor assessments up to 24 months after the first dose. The main outcomes measured are dose limiting toxicities during Phase 1a and overall response rate during Phase 1b. The study includes participants aged 18 and older with measurable disease and adequate organ function. The treatment is given intravenously every two weeks, and participants are observed until disease progression or other study endpoints.

Age: 18Years +All GendersPhase 1
6 locations